Fast track approval of mRNA vaccine platforms

Introduction

Fast-track approval of mRNA vaccine platforms refers to accelerated regulatory procedures designed to evaluate and authorise messenger RNA (mRNA)-based vaccines within shorter timelines while maintaining essential standards of safety, quality and efficacy. mRNA vaccines represent an important advancement in biotechnology because they use genetic instructions to enable human cells to produce a specific antigen that stimulates an immune response.

Unlike conventional vaccines that may use weakened or inactivated pathogens or purified antigens, mRNA vaccines use synthetic messenger RNA enclosed within delivery systems, commonly lipid nanoparticles. This technology allows vaccine developers to modify vaccine candidates relatively quickly when new infectious diseases or emerging variants appear.

The COVID-19 pandemic demonstrated the importance of accelerated vaccine development and regulatory review. Consequently, governments and international health organisations have strengthened regulatory pathways for emergency authorisation, rolling reviews, conditional approvals and platform-based vaccine development.

In India, fast-track approval of mRNA vaccine platforms involves the Central Drugs Standard Control Organisation (CDSCO), the Ministry of Health and Family Welfare, the Department of Biotechnology and applicable provisions of the Drugs and Cosmetics Act, 1940 and New Drugs and Clinical Trials Rules, 2019.

Meaning and objectives of fast-track approval

Fast-track approval is a regulatory mechanism that allows promising medical products to undergo expedited scientific evaluation where there is a significant public health need.

In the context of mRNA vaccines, accelerated approval may involve early regulatory consultation, parallel evaluation of available research data, rolling submission of clinical evidence and prioritisation of regulatory reviews.

The major objectives include:

Reducing unnecessary delays in vaccine development.

Supporting rapid responses to emerging infectious diseases.

Encouraging biotechnology innovation.

Ensuring timely access to potentially life-saving vaccines.

Promoting collaboration between regulatory authorities and vaccine manufacturers.

Maintaining scientific evaluation despite accelerated timelines.

Strengthening preparedness for future public health emergencies.

Scientific foundation of mRNA vaccine platforms

mRNA vaccine technology works by introducing synthetic messenger RNA into cells. The mRNA contains instructions for producing a selected antigen.

The immune system recognises the antigen and develops an immune response.

The major components include:

Messenger RNA: Carries genetic instructions for antigen production.

Lipid nanoparticles: Protect the mRNA and facilitate cellular delivery.

Antigen expression: Cells temporarily produce the selected antigen.

Immune response: The immune system recognises the antigen and develops protective responses.

The platform can be adapted to target different pathogens by changing the genetic sequence encoding the antigen.

However, each new vaccine candidate still requires appropriate assessment of its composition, manufacturing consistency, safety, immunogenicity and clinical performance. Platform familiarity does not automatically establish the safety or effectiveness of every new vaccine.

Legal framework governing fast-track approval in India

1. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 provides the principal statutory foundation for regulating drugs and biological products in India.

It establishes requirements concerning the manufacture, import, distribution and sale of drugs.

mRNA vaccines intended for human use must comply with applicable statutory requirements and regulatory permissions.

The Act also provides the legal basis for regulatory supervision of pharmaceutical manufacturing and quality standards.

2. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019 establish procedures for clinical trial permissions, new drug approvals and regulatory oversight.

These rules are particularly important for mRNA vaccines because they require appropriate scientific evidence concerning safety and efficacy.

The regulatory framework provides for consideration of special circumstances, including public health emergencies, subject to applicable requirements.

3. Central Drugs Standard Control Organisation (CDSCO)

CDSCO functions under the Ministry of Health and Family Welfare and is India's principal national regulatory authority for drugs and certain biological products.

Its responsibilities include:

Evaluating clinical trial applications.

Reviewing vaccine safety and efficacy data.

Granting applicable regulatory permissions.

Supervising pharmaceutical quality requirements.

Monitoring regulatory compliance.

The Drugs Controller General of India (DCGI) plays an important role in the approval of new drugs and vaccines.

4. Environment (Protection) Act, 1986

The Environment (Protection) Act, 1986 may become relevant where biotechnology research or manufacturing activities involve genetically engineered microorganisms or other regulated biological materials.

The 1989 Rules governing genetically engineered organisms establish safeguards for specified activities involving genetically engineered microorganisms and organisms.

Applicable requirements depend on the nature of the biological material and the particular research or manufacturing activity.

5. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 regulates access to biological resources and associated traditional knowledge, subject to its statutory scope and exemptions.

Vaccine research involving biological resources obtained from India may require consideration of applicable access and benefit-sharing requirements.

The Biological Diversity (Amendment) Act, 2023 modified several provisions of the original framework.

Major mechanisms for fast-track approval

1. Rolling review

Rolling review allows regulatory authorities to examine available scientific data as it becomes available instead of waiting for the complete application.

For mRNA vaccine candidates, manufacturing information, non-clinical findings and clinical trial results may be submitted in stages, subject to regulatory procedures.

This approach can reduce administrative delays while maintaining scientific scrutiny.

2. Emergency use authorisation

Emergency use authorisation allows regulators to permit the use of certain medical products during serious public health emergencies when applicable legal and scientific conditions are satisfied.

Such authorisation generally involves an assessment of available safety, efficacy and quality evidence.

Emergency authorisation should not be confused with unconditional or permanent marketing approval.

3. Conditional marketing authorisation

Conditional marketing authorisation allows a product to receive approval subject to specified conditions, including additional evidence generation and post-authorisation monitoring.

It is particularly relevant when a serious public health need exists but some evidence remains outstanding.

4. Platform-based regulatory assessment

An mRNA vaccine platform may use an established technological foundation, including a delivery system and manufacturing process.

Previous platform experience can support the evaluation of certain technical characteristics.

However, regulators must still examine candidate-specific factors, including:

Antigen selection.

mRNA sequence characteristics.

Product composition.

Manufacturing consistency.

Clinical safety.

Immune response.

Clinical effectiveness.

A previously approved platform does not automatically authorise a new vaccine candidate.

5. Accelerated manufacturing and quality review

Regulatory authorities may prioritise the review of manufacturing facilities, quality systems and production documentation.

For mRNA vaccines, quality assessment may include identity, purity, potency, stability, lipid nanoparticle characteristics and batch consistency.

International regulatory framework

1. World Health Organization (WHO)

The WHO provides international guidance on vaccine quality, safety, efficacy and regulatory preparedness.

Its Emergency Use Listing (EUL) procedure supports the assessment of medical products during public health emergencies.

The WHO framework also encourages regulatory cooperation and reliance on reliable scientific assessments.

2. United States Food and Drug Administration (USFDA)

The USFDA provides accelerated regulatory pathways for eligible medical products.

Important mechanisms include:

Fast Track designation.

Breakthrough Therapy designation.

Accelerated Approval.

Priority Review.

Emergency Use Authorization.

These mechanisms have different eligibility requirements and are not interchangeable.

3. European Medicines Agency (EMA)

The European Medicines Agency provides accelerated assessment procedures and rolling reviews for eligible medicinal products.

Its regulatory framework allows early scientific engagement and expedited evaluation where public health considerations justify such procedures.

4. International Council for Harmonisation (ICH)

ICH develops international technical guidelines relating to pharmaceutical quality, safety and clinical evaluation.

Its guidelines support harmonisation of regulatory requirements and improve the consistency of scientific assessments across jurisdictions.

Important case laws and judicial principles

1. Association of Medical Super Speciality Aspirants and Residents v. Union of India (2019)

The Supreme Court considered issues concerning regulatory standards and the importance of maintaining prescribed requirements in medical education.

The judgment emphasised that regulatory requirements should not be relaxed arbitrarily where public interest and institutional standards are involved.

Relevance: Fast-track vaccine approvals must balance administrative efficiency with the maintenance of essential scientific and regulatory standards. Expedited procedures should not become a justification for ignoring mandatory safety requirements.

2. Jacob Puliyel v. Union of India (2022)

The Supreme Court considered issues concerning COVID-19 vaccination policies, vaccine-related information and individual autonomy.

The judgment emphasised the importance of transparency in vaccine safety information and recognised that bodily autonomy is protected under Article 21.

Relevance: Accelerated mRNA vaccine approvals must be supported by transparent scientific information, appropriate disclosure of safety findings and respect for individual medical autonomy.

3. Common Cause v. Union of India (2018)

The Supreme Court recognised the importance of dignity and individual autonomy in medical decision-making.

The judgment examined the right to die with dignity and advance medical directives.

Relevance: Vaccine approval and administration policies must respect individual autonomy and informed medical decision-making, subject to applicable public health laws.

4. Navtej Singh Johar v. Union of India (2018)

The Supreme Court emphasised constitutional values of dignity, equality and individual autonomy under Articles 14, 15 and 21.

The judgment strengthened the constitutional understanding of personal choice and human dignity.

Relevance: Regulatory policies concerning mRNA vaccines should respect equality, dignity and individual autonomy while ensuring fair access to approved medical technologies.

5. Justice K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms.

The judgment established important principles concerning informational privacy and personal autonomy.

Relevance: mRNA vaccine clinical trials and post-marketing monitoring involve the collection of health information. Regulatory authorities and manufacturers must ensure appropriate confidentiality and protection of personal medical data.

Challenges in fast-track approval of mRNA vaccines

Fast-track approval creates several scientific, regulatory and ethical challenges.

First, accelerated regulatory procedures may create difficulties when long-term safety information is not yet available.

Second, mRNA vaccine manufacturing requires specialised infrastructure, quality control and temperature-management systems.

Other important challenges include:

Limited long-term clinical evidence during emergency situations.

Manufacturing consistency across production batches.

Potential adverse reactions requiring continued monitoring.

Cold-chain and storage requirements.

High research and development costs.

Differences in international regulatory standards.

Public concerns regarding vaccine safety.

Intellectual property and technology-transfer disputes.

Suggestions for strengthening fast-track approval mechanisms

India should strengthen its regulatory infrastructure to support rapid but scientifically rigorous evaluation of mRNA vaccine platforms.

Important measures include:

Establishing specialised mRNA vaccine assessment teams.

Encouraging early regulatory consultation with manufacturers.

Strengthening rolling-review procedures.

Improving clinical trial infrastructure.

Establishing robust post-marketing surveillance systems.

Ensuring transparent communication of safety information.

Supporting domestic mRNA manufacturing capabilities.

Harmonising relevant regulatory standards with international guidelines.

Strengthening pharmacovigilance and adverse-event reporting.

Promoting cooperation between CDSCO, DBT, research institutions and biotechnology companies.

Regulatory authorities should also establish clear criteria for distinguishing platform-level evidence from candidate-specific clinical evidence.

Conclusion

Fast-track approval of mRNA vaccine platforms is an important regulatory mechanism for accelerating the development and availability of innovative vaccines during public health emergencies. These platforms offer significant advantages because their genetic sequences can be adapted to target different infectious diseases.

India's Drugs and Cosmetics Act, 1940, New Drugs and Clinical Trials Rules, 2019 and CDSCO regulatory framework provide the principal legal foundation for vaccine approval and supervision.

Judicial decisions such as Jacob Puliyel v. Union of India, Justice K.S. Puttaswamy v. Union of India and Common Cause v. Union of India establish important principles concerning vaccine transparency, privacy, dignity and individual autonomy.

An effective fast-track approval framework must combine accelerated scientific review, manufacturing quality assurance, clinical evidence, transparent regulatory decisions and continuous safety monitoring. Such an approach can encourage biotechnology innovation while ensuring that faster vaccine availability does not compromise public health and patient safety.